Doosan Enerbility Shares Fall Below 80,000 Won; New Week Rebound Hinges on US September CPI·PPI Releases and Korea-US Nuclear Cooperation
With Doosan Enerbility (034020) shares having fallen below the 80,000-won mark, attention is focused on how the stock will move in the new trading week beginning on the 12th. Scheduled releases of key US economic indicators and moves to expand Korea-US nuclear cooperation are being cited as variable

With Doosan Enerbility (034020) shares having fallen below the 80,000-won mark, attention is focused on how the stock will move in the new trading week beginning on the 12th. Scheduled releases of key US economic indicators and moves to expand Korea-US nuclear cooperation are being cited as variables that will shape domestic and international market conditions and determine the stock's direction.
■ Closed Below 80,000 Won... Will It Rebound?
Doosan Enerbility recently slipped below the 80,000-won level, drawing growing attention to the stock's direction. In the session on the 8th, it closed at 76,700 won, down 4.72%. For the new week, key points of interest include whether the stock can re-enter the 80,000-won range and how overall investment sentiment toward nuclear power-related stocks will move.
■ US September CPI and PPI Releases in Focus
Externally, US inflation indicators are the major variable. The US September Consumer Price Index (CPI) and Producer Price Index (PPI) are scheduled for release in the new week. These two indicators are key data for gauging the US inflation situation and serve as an important basis for forecasting the Federal Reserve's (Fed) future monetary policy.
If inflationary pressure proves stronger than expected, market expectations for the US interest rate path could change. Conversely, if a trend of price stability is confirmed, it could also affect investment sentiment.
How the New York stock market reacts following the releases of these economic indicators also warrants attention. Movements in the US market can influence the domestic market, and are thus expected to be a variable for the share price movements of major stocks including Doosan Enerbility.
■ Korea-US Nuclear Cooperation... "Includes Plan to Build 8 Large Nuclear Plants in the US"
Meanwhile, changes are also appearing in the external environment surrounding the nuclear power industry. The recently unveiled Korea-US nuclear cooperation plan includes a scheme to build eight large nuclear plants in the United States. Of these, two would use the Korean-designed APR1400 reactor, while the remaining six would use the AP1000 from US-based Westinghouse.
Some analysts say tensions between the United States and Canada partly influenced this cooperation plan. With Canadian companies holding stakes in Westinghouse, the interpretation is that trade disputes between the two countries combined with Washington's push to secure leadership in the nuclear industry lent momentum to expanding cooperation with South Korea.
The two countries are also reportedly pursuing adjustments to the existing intellectual property-related agreement between Korea Electric Power Corporation, Korea Hydro & Nuclear Power, and Westinghouse, alongside expanding nuclear project cooperation.
■ Time Needed Before Orders and Contracts... Calls for Caution on Optimism
However, it may take time before the nuclear construction plans translate into actual orders and contracts. As participating companies and contract sizes for each project have yet to be determined, it is difficult to conclude that expectations of expanded cooperation will immediately lead to improved performance for Doosan Enerbility.
Doosan Enerbility's share price in the new week is expected to seek direction amid the interplay of global market reactions to US inflation data and issues surrounding the nuclear power industry. Investors are watching closely whether Doosan Enerbility, continuing to trade below 80,000 won, can secure a rebound or whether the correction will persist.
[※ This article is for informational purposes only and does not constitute a recommendation to buy or sell any specific stock. The final investment decision and responsibility rest with the investor.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.
![[Breaking] HLB Submits FDA Resubmission for Liver Cancer First-Line Treatment Rivoceranib and Camrelizumab... Review Period Up to 6 Months](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F09%2F604784%2F7d11344647c6914a%2Fvariants%2Fhero.webp&w=1920&q=75)


